Chief Scientific Officer
Marion Dorsch joined Atavistik Bio as President and Chief Scientific Officer in April 2021. As Chief Scientific Officer, Marion Dorsch oversees the drug discovery and translational research activities to advance Atavistik Bio’s pipeline. She is an accomplished scientist and senior executive with a proven track record of discovering and advancing innovative therapies to patients in oncology, rare genetic diseases, and inflammation. Marion joined Atavistik Bio from Blueprint Medicines where she served as Chief Scientific Officer and oversaw the progression of a strong portfolio of precision medicines. Prior to Blueprint Medicines, Marion was the Vice President of Biology at Agios Pharmaceuticals, Director of Cancer Biology at Sanofi Oncology, Group leader in Oncology at the Novartis and part of the Inflammation group at Millennium Pharmaceuticals. During her tenure in biotech and pharma, Marion has made major contributions to the discovery and development of more than 6 FDA-approved precision medicines.
Marion received her PhD in Biology from the Free University of Berlin, Germany and was a postdoctoral fellow in the laboratory of Dr. Stephen Goff at Columbia University in New York.